Trial Profile
A Pilot Study of Galunisertib (LY2157299) Plus Stereotactic Body Radiotherapy (SBRT) in Patients With Advanced Hepatocellular Carcinoma (HCC)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 31 Mar 2023
Price :
$35
*
At a glance
- Drugs Galunisertib (Primary)
- Indications Liver cancer
- Focus Adverse reactions
- 09 Dec 2020 Planned End Date changed from 1 Jan 2021 to 1 Jan 2022.
- 09 Dec 2020 Planned primary completion date changed from 1 Jan 2021 to 1 Jan 2022.
- 25 Jun 2020 Planned End Date changed from 1 Jan 2019 to 1 Jan 2021.